GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.
GSK shares jump on $2.2 billion Zantac settlement
By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with a suspected carcinogen.
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
Pharma company reaches $2.2B settlement in Zantac lawsuits
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer,
BGR26d
FDA warns of cancer-causing impurity in popular heartburn drug Zantac
People taking OTC ranitidine could consider using other OTC medicines approved for their condition. There are multiple drugs on the market that are approved for the same or similar uses as ...
Medical Xpress4d
Zantac maker GSK agrees to pay $2.3 bn in US settlements
British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits alleging that its Zantac heartburn drug caused cancer. "GSK today ...
Becker's Hospital Review23d
Zantac cancer trial results in hung jury
A Chicago jury failed to reach a verdict Sept. 18 over claims that heartburn drug Zantac causes cancer, Reuters exclusively reported. The case, brought by Illinois resident Ronald Kimbrow ...
STAT4d
The company also agreed to pay $70 million to settle a whistleblower lawsuit
After protracted legal battling, GSK has agreed to pay up to $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
FiercePharma3d
GSK will pony up $2.2B to resolve 80K Zantac cases
GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...
Daily Breeze4d
GSK to settle 80,000 Zantac cases for up to $2.2 billion
ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from ...